Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants

Vaccine

Volumn 28, Issue 14, 2010, Pages 2598-2606

  Cho, Hee Jeong ^a   Kim, Ji Yeon ^a   Lee, Young ^a   Kim, Jung Mogg ^b   Kim, Young Bong ^c   Chun, Taehoon ^a   Oh, Yu Kyoung ^d  

^a Korea University   (South Korea)

^b Hanyang University   (South Korea)

^c Konkuk University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Human papillomavirus; Mucosal vaccination; Sublingual adjuvant; Sublingual route

Indexed keywords

CHOLERA TOXIN B SUBUNIT; COLECALCIFEROL; GAMMA INTERFERON; GLUTAMIC ACID DERIVATIVE; HUMAN PAPILLOMAVIRUS 16 L1 VACCINE; IMIQUIMOD; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; MURABUTIDE; MURAMYL DIPEPTIDE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; PEPTIDOGLYCAN; PHOSPHORYL LIPID A; POLY GAMMA GLUTAMIC ACID; POLYINOSINIC POLYCYTIDYLIC ACID; SECRETORY IMMUNOGLOBULIN; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, SUBLINGUAL; ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES;

EID: 77649179585     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.013     Document Type: Article

References (41)

1. De Magistris M.T. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 58 (2006) 52-67
2. Makidon P.E., Bielinska A.U., Nigavekar S.S., Janczak K.W., Knowlton J., Scott A.J., et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS ONE 3 (2008) e2954
3. Glezen W.P. Universal influenza vaccination and live attenuated influenza vaccination of children. Pediatr Infect Dis J 27 10 (Suppl.) (2008) S104-S109
4. van Ginkel F.W., Jackson R.J., Yoshino N., Hagiwara Y., Metzger D.J., Connell T.D., et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun 73 (2005) 6892-6902
5. BenMohamed L., Belkaid Y., Loing E., Brahimi K., Gras-Masse H., and Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol 32 (2002) 2274-2281
6. Çuburu N., Kweon M.-N., Song J.H., Hervouet C., Luci C., Sun J.B., et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25 (2007) 8598-8610
7. Song J.H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.Y., Park S.H., et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 105 (2008) 1644-1649
8. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 (2005) S45-S53
9. Schiller J.T., and Lowy D.R. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res 66 (2006) 10229-10232
10. Schwarz T.F. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines 7 (2008) 1465-1473
11. Cho H.J., Hahm M.S., Kim M.K., Han I.K., Jung W.W., Choi H.G., et al. Expression, purification, and antibody binding activity of human papillomavirus 16 L1 protein fused to maltose binding protein. Protein Pept Lett 14 (2007) 417-424
12. Lindsay G.K., Roslansky P.F., and Novitsky T.J. Single-step, chromogenic limulus amebocyte lysate assay for endotoxin. J Clin Microbiol 27 (1989) 947-951
13. Han I.K., Kim Y.B., Kang H.S., Sul D., Jung W.W., Cho H.J., et al. Thermosensitive and mucoadhesive delivery systems of mucosal vaccines. Methods 38 (2006) 106-111
14. Oh Y.K., Park J.S., Yoon H., and Kim C.K. Enhanced mucosal and systemic immune responses to a vaginal vaccine coadministered with RANTES-expressing plasmid DNA using in situ-gelling mucoadhesive delivery system. Vaccine 21 (2003) 1980-1998
15. Oh Y.K., Sohn T., Park J.S., Kang M.J., Choi H.G., Kim J.A., et al. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant. Virology 328 (2004) 266-273
16. Cho H.J., Shin H.J., Han I.K., Jung W.W., Kim Y.B., Sul D., et al. Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. Vaccine 25 (2007) 8049-8057
17. Cui Z., and Mumper R.J. Biolayer films for mucosal (genetic) immunization via the buccal route in rabbits. Pharm Res 19 (2002) 947-953
18. Asahi-Ozaki Y., Itamura S., Ichinohe T., Strong P., Tamura S., Takahashi H., et al. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect 8 (2006) 2706-2714
19. Pashine A., Valiante N.M., and Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11 (2005) S63-S68
20. Wille-Reece U., Flynn B.J., Loré K., Koup R.A., Miles A.P., Saul A., et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203 (2006) 1249-1258
21. Kanneganti T.D., Lamkanfi M., and Núñez G. Intracellular NOD-like receptors in host defense and disease. Immunity 27 (2007) 549-559
22. Moschos S.A., Bramwell V.W., Somavarapu S., and Alpar H.O. Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A. Vaccine 24 (2006) 1081-1086
23. Adams J.S., and Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 4 (2008) 80-90
24. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 178 (2007) 2979-2986
25. Wang X., Uto T., Akagi T., Akashi M., and Baba M. Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine. J Med Virol 80 (2008) 11-19
26. Mizuno D., Ide-Kurihara M., Ichinomiya T., Kubo I., and Kido H. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal sIgA production in response to the influenza virus antigen. J Immunol 176 (2006) 1122-1130
27. Park J.S., Oh Y.K., Kang M.J., and Kim C.K. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. J Med Virol 70 (2003) 633-641
28. Durand V., Wong S.Y., Tough D.F., and Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol Cell Biol 82 (2004) 596-602
29. Enioutina E.Y., Bareyan D., and Daynes R.A. TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines. Vaccine 26 (2008) 601-613
30. Fraillery D., Zosso N., and Nardelli-Haefliger D. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles. Vaccine 27 (2009) 2326-2334
31. Raman V.S., O'Donnell J., Bailor H.R., Goto W., Lahiri R., Gillis T.P., et al. Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection. Infect Immun 77 (2009) 5623-5630
32. van Ginkel F.W., Jackson R.J., Yuk Y., and McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165 (2000) 4778-4782
33. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., and McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20 (2002) 2431-2438
34. Huang C.F., Wang C.C., Wu T.C., Wu K.G., Lee C.C., and Peng H.J. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice. J Pediatr Gastroenterol Nutr 46 (2008) 262-271
35. Goto N., Maeyama J., Yasuda Y., Isaka M., Matano K., Kozuka S., et al. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Vaccine 18 (2000) 2164-2171
36. Eriksson K., Fredriksson M., Nordström I., and Holmgren J. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Infect Immun 71 (2003) 1740-1747
37. Song J.H., Kim J.I., Kwon H.J., Shim D.H., Parajuli N., Cuburu N., et al. CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J Immunol 182 (2009) 6851-6860
38. Lycke N. From toxin to adjuvant: basic mechanisms for the control of mucosal sIgA immunity and tolerance. Immunol Lett 97 (2005) 193-198
39. Snider D.P., Marshall J.S., Perdue M.H., and Liang H. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J Immunol 153 (1994) 647-657
40. Takagi H., Hiroi T., Yang L., Takamura K., Ishimitsu R., Kawauchi H., et al. Efficient induction of oral tolerance by fusing cholera toxin B subunit with allergen-specific T-cell epitopes accumulated in rice seed. Vaccine 26 (2008) 6027-6030
41. Anjuère F., George-Chandy A., Audant F., Rousseau D., Holmgren J., and Czerkinsky C. Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J Immunol 170 (2003) 1586-1592